Abstract |
A 70-year-old man diagnosed with idiopathic pulmonary fibrosis (IPF) one year earlier developed progressive exertional dyspnea 3 weeks after onset of coronavirus disease 2019 (COVID-19). High-resolution computed tomography showed new extensive ground-glass opacities with rapidly progressive honeycombing. Although he was diagnosed with acute exacerbation (AE) of IPF triggered by COVID-19 and received methylprednisolone pulse therapy twice within one month, there was no improvement of oxygenation and lung involvement. Three months after COVID-19 onset, it was decided to provide best supportive care. An AE of IPF as a sequela of COVID-19, which is recognized as macrophage activation syndrome, is fatal, and in this case, the measurement of serum heme oxygenase-1, which is a macrophage activation biomarker involved in pulmonary cellular protection against oxidative stress, was useful for tracking disease activity.
|
Authors | Yu Hara, Yume Oshima, Yoichi Tagami, Ayako Aoki, Hiroaki Fujii, Ami Izawa, Kenichi Seki, Akinori Kanai, Aya Yabe, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko |
Journal | Respiratory medicine case reports
(Respir Med Case Rep)
Vol. 36
Pg. 101615
( 2022)
ISSN: 2213-0071 [Print] England |
PMID | 35223424
(Publication Type: Case Reports)
|
Copyright | © 2022 The Authors. |